Keryx Biopharmaceuticals Inc. (KERX) Stock Price Down 1.1%
Shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) were down 1.1% on Monday . The company traded as low as $7.13 and last traded at $7.17, with a volume of 693,825 shares trading hands. The stock had previously closed at $7.25.
A number of analysts have weighed in on KERX shares. FBR & Co restated an “outperform” rating and issued a $13.00 target price on shares of Keryx Biopharmaceuticals in a research report on Tuesday, May 17th. Maxim Group restated a “buy” rating and issued a $7.00 target price (up previously from $5.00) on shares of Keryx Biopharmaceuticals in a research report on Tuesday, March 29th. BTIG Research restated a “sell” rating and issued a $2.50 target price on shares of Keryx Biopharmaceuticals in a research report on Tuesday, March 29th. Cowen and Company restated a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Saturday, April 30th. Finally, Zacks Investment Research lowered shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 27th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company. Keryx Biopharmaceuticals currently has an average rating of “Hold” and an average target price of $8.91.
The firm has a 50-day moving average price of $6.28 and a 200 day moving average price of $4.93. The stock’s market capitalization is $748.68 million.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its earnings results on Thursday, April 28th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.13. During the same quarter in the previous year, the business earned ($0.28) earnings per share. The company had revenue of $6.80 million for the quarter, compared to analyst estimates of $6.63 million. The company’s revenue for the quarter was up 466.7% compared to the same quarter last year. On average, analysts expect that Keryx Biopharmaceuticals Inc. will post ($0.96) EPS for the current fiscal year.
An institutional investor recently bought a new position in Keryx Biopharmaceuticals stock. Royce & Associates LLC bought a new position in Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 341,725 shares of the biopharmaceutical company’s stock, valued at approximately $1,726,000. Royce & Associates LLC owned about 0.32% of Keryx Biopharmaceuticals as of its most recent SEC filing.
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.